

Special Issue

Evaluating the Immune Response to RNA Vaccine

Message from the Guest Editors

RNA technology has demonstrated numerous advantages in vaccine development and is widely recognized for its versatility. Specifically, it can be utilized in the development of new vaccines or therapeutics for various types of infectious or non-infectious diseases by manipulating the mRNA cargo and the lipid-based delivery system. However, we still lack a comprehensive understanding of how these vaccines work, particularly regarding their interactions with the immune system and the underlying mechanism of action implicated in the generation of high-quality vaccine responses. In this Special Issue, we seek original research articles and review articles that address the immune mechanisms of RNA vaccines. This includes, but is not limited to, innate immune signatures, the magnitude and quality of antibody responses, and the regulation of B cell and T cell compartments. These investigations provide essential guidance for the rational design of RNA vaccines.

Guest Editors

Dr. Ang Lin

Vaccine Center, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China

Dr. Huajun Zhao

School of Pharmaceutical Sciences, Shandong University, Jinan, China

Deadline for manuscript submissions

30 June 2025



Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



mdpi.com/si/210841

Vaccines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the second half of 2024).